T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.

@article{Li2014T790MMI,
  title={T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.},
  author={Wei Li and Shengxiang Ren and Jia-yu Li and Aiwu Li and Li-Hong Fan and Xuefei Li and Cao Zhao and Yayi He and Guanghui Gao and Xiao-xia Chen and Shuai Li and Jingyun Shi and Caicun Zhou and Ke Fei and Gerald Schmid-Bindert},
  journal={Lung cancer},
  year={2014},
  volume={84 3},
  pages={
          295-300
        }
}
BACKGROUND AND PURPOSE Continuous EGFR-TKI treatment beyond progression has shown promising benefit for some patients with acquired resistance to EGFR-TKIs. The aim of this study was to investigate the association of secondary T790M mutation at the time of progression with the efficacy of EGFR-TKI treatment beyond progression. METHODS From March 2011 to March 2013, patients with advanced NSCLC who developed acquired resistance to EGFR-TKI and where a re-biopsy was performed at Tongji… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 43 CITATIONS

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

  • Drug design, development and therapy
  • 2014
VIEW 2 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2018